Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
نویسندگان
چکیده
منابع مشابه
Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
GOAL To determine efficacy and safety of treatment with Rituximab and Etanercept plus Methotrexate in patients with active Rheumatoid Arthritis (RA), who had an inadequate response to nonbiologic DMARDS therapies and to explore the pharmacogenetics and pharmacodynamics of Rituximab and Etanercept in our populations. Study was done at Rheumatology Clinic of University Clinical Centre in Prishtin...
متن کاملBiologic Treatment in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease. It affects around 1% of the adult population in all age groups, although the incidence peaks during the fifth decade of life. The aetiology of RA is unknown, but it is considered to be autoimmune in nature. Inflammation in the synovial tissues of the joints is the hallmark of RA, causing pain, stiffness, loss of function and ...
متن کاملThe risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
BACKGROUND Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore we aimed to estimate the incidence of malignancy in early RA patients and to evaluate the relative risk of...
متن کاملEtanercept in the treatment of rheumatoid arthritis
Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical trials in early as well as established disease. Etanercept, along with other TNF inhibitors, have revolutionized management of RA and dramatically improved disease activity, function, quality of life and mortal...
متن کاملReview of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
Safety concerns associated with many drugs indicated for the treatment of rheumatoid arthritis (RA) can be attenuated by the early identification of toxicity through routine laboratory monitoring; however, a comprehensive review of the recommended monitoring guidelines for the different available RA therapies is currently unavailable. The aim of this review is to summarize the current guideline...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Archives
سال: 2014
ISSN: 0350-199X
DOI: 10.5455/medarh.2014.68.51-53